GNI Group

Chiba, Japan Founded: 2001 • Age: 25 yrs
Multinational company engaged in the research, development, manufacturing of pharmaceutical drugs
Annual revenue $150.4M Latest available
Total funding - Funding intelligence
Employees 867 Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors - Brand Intelligence

About GNI Group

GNI Group is a company based in Chiba (Japan) founded in 2001. The company has 867 employees as of December 31, 2024. GNI Group has completed 1 acquisition, including Ayumi Pharmaceutical.

  • Headquarter Chiba, Japan
  • Employees 867 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Gni Group Ltd.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $150.43 M (USD)
    -9.22
    as on Dec 31, 2024
  • Net Profit
    $7.01 M (USD)
    -86.43
    as on Dec 31, 2024
  • EBITDA
    $2.78 M (USD)
    -91.58
    as on Dec 31, 2024
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    867

    as on Dec 31, 2024

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of GNI Group

GNI Group is a publicly listed company on the TSE with ticker symbol 2160 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: TSE · Ticker: 2160 · Sector: Health technology · Japan

People of GNI Group

Headcount 200-500
Employee Profiles 1
Board Members and Advisors 5
Employee Profiles
People
Ying Luo
Director, Representative Executive Officer, President & CEO

Unlock access to complete

Board Members and Advisors
people
Kan-Ichiro Suzuki
Director
people
Hideaki Sashiwa
Director
people
Kanako Kikuchi
External Director
people
Ryosuke Matsui
External Director

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of GNI Group

Premium access

Detailed funding history for GNI Group

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by GNI Group

GNI Group has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Ayumi Pharmaceutical.

Investments
Premium access

Investment portfolio details for GNI Group

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Specialty generic drugs for rheumatism and orthopedics are manufactured.
Locked Locked 2015 Locked
Premium access

Complete acquisition details for GNI Group

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - GNI Group

Premium access

Detailed financials for GNI Group

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Gni Group Comparisons

GNI Group Primary company
Description
Multinational company engaged in the research, development, ...
Location
Chiba, Japan
Founded Year
2001
Annual Revenue
$150.43 M (USD)
Net Profit
$7.01 M (USD)
EBITDA
$2.78 M (USD)
Employees
867
As of 2024
Premium access

Peer comparison for GNI Group

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of GNI Group

Premium access

Detailed competitors of GNI Group

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Gni Group

Premium access

Complete news archive for GNI Group

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about GNI Group

GNI Group was founded in 2001.

GNI Group is headquartered in Chiba, Japan. It is registered at Chiba, Chiba, Japan.

As of Dec 31, 2024, the latest employee count at GNI Group is 867.

Annual revenue of GNI Group is $150.43M as on Dec 31, 2024.

Gni pharma is engaged in the research, development, manufacturing and sales of pharmaceutical drugs and traditional Chinese medicines. The drug development pipeline includes tamibarotene for acute promyelocytic leukemia under preparation for import drug registration; F351 in phase 1 for liver fibrosis and for chronic kidney failure in preclinical stage; F573 for acute chronic liver failure in investigational new drug application stage; and etuary for pulmonary fibrosis (approved), for radiation pneumonitis in phase 2, for diabetic nephropathy in preclinical stage, and connective disease in preclinical stage.

Yes, GNI Group is publicly traded on TSE under the ticker symbol 2160.

GNI Group has made 1 acquisition, including Ayumi Pharmaceutical.

The ticker symbol of GNI Group is 2160 on TSE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available